Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giddings

Showing results (861-870 of 888) with videos related to

Pageof 89
Sort By:
Carcinogenesis|May 15, 2010
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesionSebastiano Battaglia, Orla Maguire, James L Thorne, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBSHilary Schenck Eidam, John Russell, Kaushik Raha, et al.
Journal of the Intensive Care Society|November 17, 2025
Anaemia management with red blood cell transfusion to improve post-intensive care disability: Protocol for the ABC post-ICU randomised controlled trialTimothy S Walsh, Lydia Emerson, Jo Singleton, et al.
The Journal of Infectious Diseases|April 16, 2022
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)Oliver Stirrup, Maria Krutikov, Gokhan Tut, et al.
The Lancet. Healthy Longevity|July 11, 2022
Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort studyGokhan Tut, Tara Lancaster, Panagiota Sylla, et al.
Journal of Medicinal Chemistry|April 24, 2025
Discovery of a Potent, Selective, and Brain-Penetrant Checkpoint Kinase 1 Inhibitor, BEN-28010, for the Treatment of GlioblastomaMichael J Rawling, Arpita Ray-Sinha, Michael Bestwick, et al.
BMC Neurology|June 12, 2026
Stroke risk factors and outcomes in Trinidad and Tobago: the START studyNaveen Anand Seecheran, Nicole Maharaj, Steven Swarath, et al.
The Lancet. Infectious Diseases|March 14, 2022
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 studyJames Welker, Juan D Pulido, Andrew T Catanzaro, et al.
BMJ Open|December 10, 2023
Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UKTimothy Simon Walsh, Leanne M Aitken, Cathrine A McKenzie, et al.
Nature Communications|May 15, 2021
Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistanceEmily L Giddings, Devin P Champagne, Meng-Han Wu, et al.
Pageof 89

Showing results (861-870 of 888) with videos related to

Sort By:
Pageof 89
Carcinogenesis|May 15, 2010
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesionSebastiano Battaglia, Orla Maguire, James L Thorne, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBSHilary Schenck Eidam, John Russell, Kaushik Raha, et al.
Journal of the Intensive Care Society|November 17, 2025
Anaemia management with red blood cell transfusion to improve post-intensive care disability: Protocol for the ABC post-ICU randomised controlled trialTimothy S Walsh, Lydia Emerson, Jo Singleton, et al.
The Journal of Infectious Diseases|April 16, 2022
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)Oliver Stirrup, Maria Krutikov, Gokhan Tut, et al.
The Lancet. Healthy Longevity|July 11, 2022
Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort studyGokhan Tut, Tara Lancaster, Panagiota Sylla, et al.
Journal of Medicinal Chemistry|April 24, 2025
Discovery of a Potent, Selective, and Brain-Penetrant Checkpoint Kinase 1 Inhibitor, BEN-28010, for the Treatment of GlioblastomaMichael J Rawling, Arpita Ray-Sinha, Michael Bestwick, et al.
BMC Neurology|June 12, 2026
Stroke risk factors and outcomes in Trinidad and Tobago: the START studyNaveen Anand Seecheran, Nicole Maharaj, Steven Swarath, et al.
The Lancet. Infectious Diseases|March 14, 2022
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 studyJames Welker, Juan D Pulido, Andrew T Catanzaro, et al.
BMJ Open|December 10, 2023
Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UKTimothy Simon Walsh, Leanne M Aitken, Cathrine A McKenzie, et al.
Nature Communications|May 15, 2021
Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistanceEmily L Giddings, Devin P Champagne, Meng-Han Wu, et al.
Pageof 89